Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice

Oncotarget. 2018 Jul 13;9(54):30472. doi: 10.18632/oncotarget.25791.

Authors

Patrick M Reeves¹, Mojgan A Abbaslou¹, Farah R W Kools¹, Kritchai Vutipongsatorn¹, Xiaoyun Tong¹, Christina Gavegnano², Raymond F Schinazi², Mark C Poznansky¹

Affiliations

¹ Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA.
² Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.21541.].

Publication types

Published Erratum